GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Change In Prepaid Assets

Contineum Therapeutics (Contineum Therapeutics) Change In Prepaid Assets : $0.69 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Change In Prepaid Assets?

Contineum Therapeutics's Change In Prepaid Assets for the quarter that ended in Mar. 2024 was $0.71 Mil. It means Contineum Therapeutics's Prepaid Assets increased by $0.71 Mil from Dec. 2023 to Mar. 2024 .

Contineum Therapeutics's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was $-1.28 Mil. It means Contineum Therapeutics's Prepaid Assets declined by $1.28 Mil from Dec. 2022 to Dec. 2023 .


Contineum Therapeutics Change In Prepaid Assets Historical Data

The historical data trend for Contineum Therapeutics's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Change In Prepaid Assets Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Change In Prepaid Assets
-0.38 -0.38 -1.28

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Change In Prepaid Assets Get a 7-Day Free Trial 0.08 -0.06 - -0.02 0.71

Contineum Therapeutics Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus